Aurora Kinase

Items 1 to 25 of 27 total

per page
  1. 1
  2. 2

Set Descending Direction
Catalog No. Product Name Application Product Information

AMG 900

Aurora Kinase inhibitor
AMG 900 is a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
A10095 SALE


Aurora/JAK inhibitor
AT9283 inhibits aurora kinase A and B and targets other tyrosine and serine/threonine kinases associated with myeloid cell proliferation.

Aurora A Inhibitor I

Aurora A Inhibitor

Aurora A Inhibitor I is a potent and selective inhibitor of Aurora A kinase (AurA), with IC50 values to be 3.4 nM (Aurora A) and unusually high selectivity 1000 fold against Aurora B; a useful tool compound for investigating the cellular role of Aurora A kinases.



Aurora Kinase inhibitor
AZD1152 is a pro-drug that rapidly undergoes phosphatase-mediated cleavage in serum to release barasertib-hQPA, a selective Aurora B kinase inhibitor that has shown preliminary activity in clinical studies of patients with acute myeloid leukemia (AML).
A10109 SALE

AZD1152-HQPA (Barasertib)

Aurora Kinase B inhibitor
AZD 1152-HQPA is a highly potent and selective inhibitor of Aurora B, with Ki values to be 0.36 (Aurora B) and 1369 nM (Aurora A) respectively and has a high specificity versus a panel of 50 other kinases.
A15762 SALE


MEK/Aurora Inhibitor
BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.


Aurora Inhibitor

CCT129202 is a representative of a structurally novel series of imidazopyridine small-molecule inhibitors of Aurora kinase activity. It shows high selectivity for the Aurora kinases over a panel of other kinases tested and inhibits proliferation in multiple cultured human tumor cell lines.



Aurora Kinase inhibitor
CCT137690 is a potent inhibitor of Aurora kinases that inhibits Aurora A and B kinases with low nanomolar IC50 values in both biochemical and cellular assays.
A10248 SALE


Aurora Kinase inhibitor
Aurora kinase/VEGFR 2 inhibitor CYC116 inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis.
A10715 SALE

Danusertib (PHA-739358)

Aurora inhibitor
Danusertib (PHA-739358) is a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor
A10352 SALE


Aurora Inhibitor
ENMD-2076 is a novel, orally-active antimitotic and antiangiogenic molecule inhibits Aurora A as well as tyrosine kinases that drive tumor vascularization, including VEGFR2 (KDR), PDGFR and the FGF receptors.
A11168 SALE


Aurora Kinase inhibitor

GSK1070916 is a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.

A10448 SALE


Aurora Kinase inhibitor
Hesperadin is a human Aurora B inhibitor with an IC50 of 40 nM for the prevention of the phosphorylation of substrate.


Aurora Inhibitor
JNJ-7706621 is a novel cell cycle inhibitor that showed potent inhibition of several cyclin-dependent kinases (CDK) and Aurora kinases.
A10508 SALE


Aurora Inhibitor
KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
A11410 SALE

MK-5108 (VX-689)

Aurora Kinase inhibitor
MK-5108, also known as VX-689, is a competitive inhibitor of the ATP-binding site of aurora A kinase.
A13396 SALE


Aurora Kinase Inhibitor
MK-8745 is a novel Aurora-A specific inhibitor. It induces apoptotic cell death in a p53-dependent manner when tested in vitro in cell lines of multiple lineages.
A10601 SALE


Aurora Inhibitor
MLN8054 is an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo.
A10004 SALE

MLN8237 (Alisertib)

Aurora Kinase inhibitor
MLN8237 (Alisertib) is a selective Aurora kinase A inhibitor with a median IC50 of 61 nM.


Aurora Kinase inhibitor

PF-03814735 is a novel, potent, orally bioavailable, reversible inhibitor of both Aurora1 and Aurora2 kinases. PF-03814735 produces a block in cytokinesis, resulting in inhibition of cell proliferation and the formation of polyploid multinucleated cells.

A10714 SALE


Aurora inhibitor
PHA-680632 is the first representative of a new class of Aurora inhibitors with a high potential for further development as an anticancer therapeutic.
A13250 SALE


Aurora B inhibitor
Reversine, which induces the dedifferentiation and regeneration of human cells, inhibits MPS1 and Aurora B with IC50 of 6 nM and 98.5 nM, respectively.


Aurora Kinase inhibitor
SAR156497 is an exquisitely selective Aurora A, B, and C inhibitor with in vitro and in vivo efficacy with IC50 = 0.5 nM (Aurora A), 1 nM (Aurora B / incenp), 3 nM (Aurora C / incenp) respectively SAR156497 combines high in vitro potency with satisfactory metabolic stability and limited CYP 3A4 and PDE3 inhibition.


Aurora inhibitor
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
A11067 SALE


Aurora Kinase inhibitor
TAK-901 is a small-molecule inhibitor of the serine-threonine kinase Aurora B with potential antineoplastic activity.

Items 1 to 25 of 27 total

per page
  1. 1
  2. 2

Set Descending Direction